Difference between revisions of "Thrombotic microangiopathy"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) (Created page with "<span id="BackToTop"></span> <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px;...") |
m (→"How I Treat") |
||
| Line 13: | Line 13: | ||
=="How I Treat"== | =="How I Treat"== | ||
*'''2023:''' Doreille et al. [https://doi.org/10.1182/blood.2022015583 How I treat thrombotic microangiopathy in the era of rapid genomics] | *'''2023:''' Doreille et al. [https://doi.org/10.1182/blood.2022015583 How I treat thrombotic microangiopathy in the era of rapid genomics] | ||
| + | *'''2021:''' Thomas & Scully [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8555418/ How I treat microangiopathic hemolytic anemia in patients with cancer] | ||
[[Category:Thrombotic microangiopathy regimens]] | [[Category:Thrombotic microangiopathy regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Thrombotic disorders]] | [[Category:Thrombotic disorders]] | ||
Revision as of 20:44, 5 April 2023
0 regimens on this page
0 variants on this page
|
Guidelines
"How I Treat"
- 2023: Doreille et al. How I treat thrombotic microangiopathy in the era of rapid genomics
- 2021: Thomas & Scully How I treat microangiopathic hemolytic anemia in patients with cancer